The future of healthcare depends on a better-connected community. In the Future of Drug Discovery (FODD) series, we bring innovators together from academia and industry to forge new neural paths in our collective brain. Our hope is to catalyse interactions to form the next-generation treatments.
Future of Drug Discovery
Claim This Podcastby Murat Tunaboylu
5.0(7 reviews)
18 episodes
Updated Weekly
Accepts GuestsHas SponsorsLocation 🇬🇧
Podcast Overview
The future of healthcare depends on a better-connected community. In the Future of Drug Discovery (FODD) series, we bring innovators together from academia and industry to forge new neural paths in our collective brain. Our hope is to catalyse interactions to form the next-generation treatments.
Language
🇺🇲
Publishing Since
2/5/2022
2 verified contact emails on file for Future of Drug Discovery
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
May 20, 2026
AI Statistical Programming for FDA Submissions - Louise Liu - #18
<p>In this episode of Future of Drug Discovery, we speak with Louise Liu, Founder and CEO of Hill Research. </p><p>The statistical programming behind an FDA submission is one of the slower steps in clinical development. Eight programmers, six months and eight million dollars is roughly what it takes to produce the data package for a single Phase 3 trial. </p><p>Hill Research is doing that work with one person, in 90 minutes, with the help of generative AI. </p><p>In this conversation, we get into how the technology works, what the FDA thinks about the use of AI in submissions, the accountability question pharma executives are asking, and what the next decade of clinical development could look like if the rest of the pipeline catches up.</p><p>Be sure to like, rate and review the podcast if you enjoyed this episode! </p><p><br></p><p><strong>Links:</strong></p><p><br></p><p><strong>Hill Research:</strong><a href="https://www.hillresearch.ai/" target="_blank" rel="noopener noreferer"><strong> https://www.hillresearch.ai/</strong></a></p><p><strong>Louise’s LinkedIn:</strong><a href="https://www.linkedin.com/in/louise-liu-phd-mba-hill-research/" target="_blank" rel="noopener noreferer"><strong> https://www.linkedin.com/in/louise-liu-phd-mba-hill-research/</strong></a></p><p><br></p><p><strong>Visit our website:</strong><a href="https://www.antiverse.io/"> <u></u></a><a href="https://www.antiverse.io/%E2%81%A0" target="_blank" rel="noopener noreferer"><strong>https://www.antiverse.io/</strong><u></u></a></p><p><br></p><p><strong>Follow Antiverse:</strong> </p><p>LinkedIn:<strong> </strong><strong></strong><a href="https://www.linkedin.com/company/antiverse/%E2%81%A0%E2%81%A0%E2%81%A0%E2%81%A0%E2%81%A0%E2%81%A0%E2%81%A0%E2%81%A0" target="_blank" rel="noopener noreferer"><strong>https://www.linkedin.com/company/antiverse/</strong><u></u></a> </p><p>X: <a href="https://twitter.com/AntiverseHQ%E2%81%A0%E2%81%A0" target="_blank" rel="noopener noreferer"><u></u><strong>https://twitter.com/AntiverseHQ</strong></a><br></p>
September 9, 2024
Murat Tunaboylu - Antiverse: Engineering the Future of Drug Discovery (FODD #8)
<p>Are you curious about the latest advancements in AI-enabled antibody discovery? In this podcast series, we dive into the world of <a href="https://www.antiverse.io/?utm_source=fodd-series&utm_medium=social&utm_campaign=fodd-series#8" target="_blank" rel="noopener noreferer">Antiverse</a> - we are accelerating drug discovery against difficult targets, including GPCRs and ion channels, using machine learning and phage display techniques. </p> <p>Join us as we discuss our mission to target cancer, cardiovascular disease, and other challenging conditions. Discover how we leverage AI and wet lab innovation to accelerate the discovery and development of biologics. Plus, learn about our unique approach to antibody discovery, our progress with our internal pipeline of antibodies against GPCRs and other challenging targets, as well as our exciting ongoing collaborations. Tune in and join us at the forefront of antibody discovery!</p> <p><strong>Things mentioned:</strong></p> <ul> <li><strong></strong><a href="https://www.linkedin.com/in/murattunaaboylu/"><strong>Murat Tunaboylu</strong></a>, Co-Founder and CEO of Antiverse.</li> <li><a href="https://www.twistbioscience.com/" target="_blank" rel="noopener noreferer"><strong>Twist Bioscience</strong></a><strong>, </strong>a Synthetic Biology company that develops and manufactures synthetic DNA. </li> <li><em></em><a href="https://enamine.net/"><em></em></a><a href="https://www.antiverse.io/?utm_source=fodd-series&utm_medium=social&utm_campaign=fodd-series#8" target="_blank" rel="noopener noreferer"><strong>Antiverse</strong></a>, an AI-first biologics discovery company that designs antibodies against difficult -to-drug targets. </li> </ul> <ul> <li><strong>Watch the full presentation, with slides! </strong><a href="https://youtu.be/cRHxi4MWExQ" target="_blank" rel="noopener noreferer"><strong>https://youtu.be/cRHxi4MWExQ</strong></a></li> </ul> <p><br></p> <p><strong>Additional Materials: </strong></p> <ul> <li><a href="https://drive.google.com/file/d/154oLwQ-hmUye5mtH3eo1o8dF7b-c_WWe/view"></a>Contact us about your discovery projects by emailing <a href="mailto:partnerships@antiverse.io?subject=Partnership Inquiry" target="_blank" rel="noopener noreferer nofollow"><strong>partnerships@antiverse.io</strong></a>. </li> </ul> <p><strong>About Antiverse:</strong></p> <p>Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.</p>
September 9, 2024
Ben Holland - Machine Learning-Based Design of Antibodies Against Difficult Targets (FODD #9)
<p>In this captivating podcast series, we dive deep into the world of computational antibody discovery with Ben Holland, our Co-Founder and CTO at <a href="https://www.antiverse.io/?utm_source=fodd-series&utm_medium=social&utm_campaign=fodd-series#8">Antiverse</a>. Join us as we uncover the immense potential of merging computational and experimental techniques in the pursuit of revolutionary antibodies, as Ben sheds light on the strong benefits and formidable challenges encountered when targeting complex molecules such as GPCRs. With an emphasis on precision and accuracy in predicting antibody-antigen interactions, Ben shares remarkable insights and breakthroughs achieved by computational discovery techniques. Tune in and join us at the forefront of antibody discovery!</p> <p><br></p> <p><strong>Things mentioned:</strong></p> <ul> <li><strong></strong><a href="https://www.linkedin.com/in/bttholland/"><strong>Ben Holland</strong></a>, Co-Founder and CEO of Antiverse.</li> </ul> <ul> <li><em></em><a href="https://enamine.net/"><em></em></a><a href="https://www.antiverse.io/?utm_source=fodd-series&utm_medium=social&utm_campaign=fodd-series#8"><strong>Antiverse</strong></a>, an AI-first biologics discovery company that designs antibodies against difficult -to-drug targets. </li> </ul> <ul> <li><strong>Watch the full presentation, with slides! </strong><a href="https://youtu.be/v8-ZrR7L83s"><strong>https://youtu.be/v8-ZrR7L83s</strong></a></li> </ul> <ul> <li>Watch the full Computational Antibody Discovery Symposium, hosted by <a href="https://www.linkedin.com/company/the-antibody-society/">The Antibody Society</a>, <a href="https://www.linkedin.com/company/naturalantibody/">NaturalAntibody</a> and <a href="https://www.linkedin.com/company/astrazeneca/">AstraZeneca</a>! <a href="https://youtube.com/playlist?list=PLWG3bWQmCPkPPfDhqiRqKWmqHYumJXlHq" target="_blank" rel="noopener noreferer"><strong>https://youtube.com/playlist?list=PLWG3bWQmCPkPPfDhqiRqKWmqHYumJXlHq</strong></a></li> </ul> <p><br></p> <p><strong>Additional Materials: </strong></p> <ul> <li><a href="https://drive.google.com/file/d/154oLwQ-hmUye5mtH3eo1o8dF7b-c_WWe/view"></a>Contact us about your discovery projects by emailing <a href="mailto:partnerships@antiverse.io?subject=Partnership Inquiry"><strong>partnerships@antiverse.io</strong></a>. </li> </ul> <p><strong>About Antiverse:</strong></p> <p>Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.</p>
18 total episodes available
Deep-dive analytics for Future of Drug Discovery
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Future of Drug Discovery?
- How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 8 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.